Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: https://www.allarity.com
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology today announced the presentation of a poster containing data on a new DRP for the monoclonal antibody drug daratumumab. The poster is to be presented during a session at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025, in Chicago, IL. This novel predictor is d
Boston (March 24, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has engaged Shareholder Intelligence Services, LLC ("ShareIntel") to investigate potential illegal naked short selling and other potential trading irregularities by third parties in the Company's common stock. The engagement with ShareIntel is part of Allarity's commitment to protecting shareholder value and ensuring fair and transparent trading of its stock. ShareIntel utilizes its proprietary DRIL-Down™ technology, a compliance-dri
The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancerFindings may reflect stenoparib's dual PARP/Wnt pathway inhibition Boston (March 17, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor— announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in advanced Ovarian Cancer at the Society of Gynecol
Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans' Administration Special Emphasis Panel on Precision Oncology Trial builds on promising clinical evidence supporting a PARP inhibitor and temozolomide combination in Small Cell Lung Cancer Boston (March 6, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylati
Boston (March 3, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that its Board of Directors has authorized a share repurchase program, allowing for the repurchase of up to $5 million of the Company's common stock through February 28, 2026. The decision underscores the Company's confidence in its future trajectory and dedication to delivering value to both patients and shareholde
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approvalTwo patients in the ongoing phase 2 trial have now exceeded 17 months on stenoparib treatment Boston (February 24, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol
Boston (February 6, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol, Allarity will capitalize and expand on the ongoing phase 2 clinical trial data to optimize the dose of stenoparib and to refine the DRP® patient selection crit
Boston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC") regarding its agreement in principle with the SEC staff to resolve the previously disclosed SEC investigation. The settlement relates to the Company's disclosures, occurring during or prior to fiscal year 2022, regarding meetings with the United States Food and Drug Administration (the "FDA") concerning our New Drug Application ("NDA") for Dovitini
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services for external biotech clientsContinued focus on advancing stenoparib to address critical unmet needs in ovarian cancer Boston (November 18, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
10-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk's U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced seve
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the appointment of Alex Epshinsky as the Company's new Chief Financial Officer (CFO), and that the Company has granted equity awards on September 12, 2024 as a material inducement to the employment of Mr. Epshinsky. Mr. Epshinsky is a Chartered Public Accountant (CPA) and brings nearly a decade of financial leadership experience in the biotech and
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and Reduced Net Loss by 26%Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. ("Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update. The Company's Interim Chief Executive Officer, Thomas Jensen, sta
Boston (December 12, 2023) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition in its leadership. Effective immediately, James G. Cullem is no longer President and CEO. The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer. The Company has also engaged Jeremy R. Graff, Ph.D., as an Executive Advisor. Dr. Graff will work closely with Mr. Jensen and the Board
Cambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the second quarter ended June 30, 2022. On October 7, 2022, Allarity filed its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022. With this filing, the Company has addressed the cause of the non-compliant status with Nasdaq Listing Rule 5250(c)(1), as previously announced on August 26, 2022. On October 10, 2022, Nasdaq provided confirmation that upon the filing of the Com
Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent
Press release Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C. (Boston, MA) ("Wolf & Company") as the Company's independent registered public accounting firm effective immediately. The appointment of Wolf & Company has been approved by both the audit committee and the Board of Directors (the "Board") of the Company. The appointment of Wolf & Company has no immediate effect on the Company's status as bei
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press ReleaseCambridge, MA, U.S.A. (July 11, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of David A. Roth, M.D., as well as Company Interim CEO James G. Cullem, J.D., and Company Co-Founder and Senior Vice President of Investor Relations Thomas Jensen, as new members of its Board of Directors, effective July 7, 2022. Dr. Roth will bring to Allarity deep experience and exper
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release Cambridge, MA, U.S.A. (June 29, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced an executive leadership transition. Effective immediately, the Company's Board of Directors has appointed James G. Cullem, J.D., current Chief Business Officer, as interim Chief Executive Officer (CEO) and Joan Y. Brown, CPA, current Director of Financial Reporting, as
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:
Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. ("Oncoheroes"), a clini